Brief: Acorda Therapeutics Receives Nasdaq Extension To Meet Minimum Bid Price Requirement
14/02/2023 21:50
Feb 14 (Reuters) - Acorda Therapeutics Inc ACOR.O :
* ACORDA THERAPEUTICS RECEIVES NASDAQ EXTENSION TO MEET
MINIMUM
BID PRICE REQUIREMENT
Source text for Eikon: ID:nBw9vZsYva
Further company coverage: ACOR.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Acorda Therapeutics
See all newsBrief: Acorda TherapeuticsCourt Held Hearing To Consider Approval Of Sale Of Substantially All Of Co's Assets To Merz Pharmaceuticals Under Asset Sale
Brief: Acorda Says Debtors Did Not Receive More Than One Qualified Bid Before Bid Deadline, In Connection With Chapter 11 Proceedings
Live Markets: Biotech companies in 'Darwinian' world as cash remains king
U.S. FDA declines to approve Supernus' drug-device combination for Parkinson's disease (updated)
U.S. FDA declines to approve Supernus' drug-device combination for Parkinson's disease